Merck recently gained approval for a vaccine called Zostavax for preventing herpes zoster reactivation in elderly people. This live virus vaccine is unusual in that it is to prevent reemergence, not to prevent initial infection. Can the same concept be used for recurrent herpes simplex infection which is much more disabling than herpes zoster in younger people?
Latest posts by Bell Eapen (see all)
- Grounding vs RAG in Healthcare ApplicationsĀ - May 4, 2024
- To or not to LangChain - April 27, 2024
- Translational Research in Digital Health and Gen AIĀ - March 23, 2024